While this happened, H.C. Wainwright initiated its Vincerx Pharma Inc [VINC] rating to a Buy in a research note published on January 14, 2022; the price target was $25. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in late December with a ‘”an Overweight”‘ rating. SVB Leerink began covering VINC with “an Outperform” recommendation on November 01, 2021. Laidlaw started covering the stock on September 13, 2021. It rated VINC as “a Buy”.
Price Performance Review of VINC
On Tuesday, Vincerx Pharma Inc [NASDAQ:VINC] saw its stock fall -2.17% to $0.21. Over the last five days, the stock has lost -36.31%. Vincerx Pharma Inc shares have fallen nearly -21.23% since the year began. Nevertheless, the stocks have fallen -82.46% over the past one year. While a 52-week high of $9.37 was reached on 01/02/25, a 52-week low of $0.18 was recorded on 01/06/25. SMA at 50 days reached $0.2668, while 200 days put it at $0.8554.
Levels Of Support And Resistance For VINC Stock
The 24-hour chart illustrates a support level at 0.1996, which if violated will result in even more drops to 0.1921. On the upside, there is a resistance level at 0.2175. A further resistance level may holdings at 0.2279. The Relative Strength Index (RSI) on the 14-day chart is 44.32, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0020, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.80%. Stochastics %K at 11.93% indicates the stock is a buying.
How much short interest is there in Vincerx Pharma Inc?
A steep rise in short interest was recorded in Vincerx Pharma Inc stocks on 2024-12-13, dropping by -0.18 million shares to a total of 0.42 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 0.6 million shares. There was a decline of -43.0%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 25, 2021 when B. Riley Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $26 price target.
